Neulasta (Pegfilgrastim

 Neulasta (pegfilgrastim) is a leukocyte growth factor used to

• reduce the incidence of infection, as manifested by febrile neutropenia (FN), in individuals with non-myeloid malignancies receiving myelosuppressive anticancer medicines associated with a clinically significant incidence of febrile neutropenia (FN).
  
• increase survival in individuals acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Limitations of Use: This therapeutic drug is not used for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Recommended Dosage: Patients with Cancer Receiving Myelosuppressive Chemotherapy: The recommended dosage of Neulasta is a single subcutaneous (SC) injection of 6 mg administered once per chemotherapy cycle. Do not administer this medicine between 14 days before and 24 hours after the use of cytotoxic chemotherapy.

Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome: The recommended dose of Neulasta is two doses, 6 mg each, administered subcutaneously one week apart. Administer the first dose as promptly as possible after suspected or confirmed exposure to radiation levels beyond 2 gray (Gy). Administer the second dose one week after the first dose. 

• Treatment with Neulasta 6 mg/0.6 mL can cause splenic rupture, which may be fatal. Patients should report left upper abdominal or shoulder pain immediately.
  
• Severe allergic reactions, including anaphylaxis, have been reported. Discontinue Neulasta if a serious allergic reaction occurs.
  
• ARDS has been reported. Monitor for signs of acute respiratory distress and discontinue if ARDS is suspected.
  
• Neulasta commonly causes bone pain. Use analgesics to manage this side effect if necessary.
  
• Monitor white blood cell counts, as Neulasta injection can cause elevated levels, which may lead to complications.
  
• Neulasta therapy can cause kidney inflammation. Monitor for signs such as swelling, decreased urine output, and blood in the urine.

What documents are required to import NEULASTA to India?

NEULASTA (pegfilgrastim) injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
  
• Import permit if applicable

NEULASTA (pegfilgrastim injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Neulasta in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of NEULASTA (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for the Neulasta injection price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source the NEULASTA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Neulasta®?

Pegfilgrastim is a Generic Name for the trade name drug Neulasta®.

What is the Manufacturer’s Name of Neulasta®?

Neulasta® is manufactured by Amgen Inc.

Is Neulasta® approved by the FDA?

Yes, Neulasta® is approved by the FDA. Date of first approval: January 31, 2002.

What is the dosage and form of Neulasta® supplied?

Neulasta® is supplied as an Injection: 6 mg/0.6 mL solution in a single-dose prefilled syringe for manual use only and co-packaged with the on-body injector. 

What are the most common side effects of Neulasta®? 

The most common side effects of Neulasta® are bone pain and pain in extremity.

How much does Neulasta® cost in India?

Prices may fluctuate over time due to market dynamics and regulatory changes. To obtain accurate and up-to-date information on the cost of Neulasta in India, it is recommended to Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Neulasta®?

Store Neulasta® in a refrigerator at 36°F to 46°F (2°C to 8°C); protect from light and do not freeze.

Is it safe to buy Neulasta® online in India?

Yes, one can buy Neulasta online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Neulasta® through legal channels.